Loading...
Please wait, while we are loading the content...
Similar Documents
Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Shapiro, Shelley M. Oudiz, Ronald J. Cao, Tian-Sheng Romano, Matthew Beckmann, X. Joy Georgiou, D. Sreedhar Mandayam Ginzton, Leonard E. Brundage, Bruce H. |
| Copyright Year | 1997 |
| Abstract | OBJECTIVES This study sought to determine the long-term effects of continuous infusion of epoprostenol (epo) therapy on survival and pulmonary artery pressure in patients with primary pulmonary hypertension (PPH). BACKGROUND PPH is a progressive disease for which there are few effective therapies. METHODS Patients with PPH and New York Heart Association functional class III or IV symptoms of congestive heart failure underwent right heart catheterization and Doppler-echocardiography to measure the maximal systolic pressure gradient between the right ventricle and right atrium (delta P) and cardiac output (CO). Doppler-echocardiography and catheterization data were compared. Patients were followed up long term with Doppler-echocardiography. RESULTS Of 69 patients who went on to receive epo, 18 were followed up for > 330 days (range 330 to 700). During long-term follow-up, there was a significant reduction in delta P, which decreased from 84.1 +/- 24.1 to 62.7 +/- 18.2 (mean +/- SD, p < 0.01). A Kaplan-Meier plot of survival of our study patients demonstrated improved survival compared with that of historical control subjects. The 1-, 2- and 3-year survival rates for our patients were 80% (n = 36), 76% (n = 22) and 49% (n = 6) compared with 10- (88%, n = 31), 20- (56%, n = 27) and 30-month (47%, n = 17) survival rates in historical control subjects. CONCLUSIONS Patients receiving continuous infusion of epo for treatment of PPH experience a decrease in pulmonary artery pressure. Long-term follow-up of this single-center patient group demonstrated improved long-term survival during epo therapy compared with that in historical control subjects and confirms predicted improved outcomes based on shorter follow-up periods. |
| Starting Page | 85 |
| Ending Page | 93 |
| Page Count | 9 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://phcenter.labiomed.org/JACC.pdf |
| PubMed reference number | 9247503v1 |
| Volume Number | 30 |
| Issue Number | 2 |
| Journal | Journal of the American College of Cardiology |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Calcium Channel Blockers Cardiac Catheterization Procedures Cardiac Output Echocardiography Eighty Epoprostenol Estimated Follow-Up Report Forty Nine Heart Failure, Right-Sided Heart Ventricle Heart failure Heart valve disease Hemodynamics Hypertensive disease Idiopathic Pulmonary Fibrosis Long-term Follow-up Mandibular right second molar tooth Patients Physiological Sexual Disorders Pulmonary Hypertension Pulmonary Valve Insufficiency Pulmonary artery structure Right side of heart Right ventricular structure Sixty Nine Systolic Pressure Transthoracic echocardiography benefit |
| Content Type | Text |
| Resource Type | Article |
